Login to Your Account



BioInvent Tumbles on Double Blow to ThromboGenics Deal

By Cormac Sheridan
Staff Writer

Wednesday, June 6, 2012
The strategic alliance between BioInvent International AB and ThromboGenics NV received a double whammy, as the two companies halted development of an anticoagulation antibody, TB-402, following unfavorable data from a Phase IIb head-to-head trial against Xarelto (rivaroxaban), while Roche Holding AG decided to exit a three-way alliance to develop an angiogenesis inhibitor, TB-403.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription